Stockreport

Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery [Yahoo! Finance]

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF lowered the firm's price target on Ultragenyx to $50 from $55 and kept an Overweight rating on the shares. The firm projects continued outperformance for US SMID-cap bio [Read more]